Participated · Seed · Sep 2025

MadSci (Madison Scientific) is developing the SmartShunt Hydrocephalus Management System, designed to integrate diagnostic and therapeutic functions for personalized hydrocephalus care. The SmartShunt System is a novel platform under development and is not yet authorized for use or available for sale in any country. Proceeds from the financing will accelerate product development, expand preclinical experience, and support team growth. Hydrocephalus affects at least one million children and adults in the U.S., and current treatments face high failure rates and diagnostic uncertainty, creating a significant unmet clinical need. Company leadership and investors cited strong confidence in MadSci’s technology and strategy to deliver improved solutions for patients and families. Madison Scientific is an early‑stage medical device company developing smart electro‑mechanical devices to improve treatment and long‑term care for patients with hydrocephalus and other neurologic conditions. Its lead product, the SmartShunt System, is designed to integrate diagnostic and therapeutic functions, and features a proprietary valve, an intracranial pressure (ICP) sensor, and advanced algorithms to optimize shunt drainage. The system aims to leverage ICP readings to reduce life‑threatening shunt failures and to enable on‑demand, personalized patient management. The SmartShunt is under development and is not yet authorized for use or available for sale in any country. Madison Scientific highlights the large addressable need — hydrocephalus affects roughly one million children and adults in the U.S. — and cites high failure rates for traditional shunts (nearly 40% within the first year).